# Tomocube

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tomocube

- Industry: Medical Devices & Equipment
- Headquarters: Daejeon, South Korea
- Website: www.tomocube.com
- Total disclosed funding: $38M
- Latest round: Series C (Sep 23, 2021)
- Investors on record: 12

## About

Based in South Korea, Tomocube is a developer of advanced 3D microscopic imaging technology, providing innovative tools for non-invasive observation of biological samples to enhance research capabilities.Founded in 2015 in Daejeon, South Korea, Tomocube develops cutting-edge 3D imaging technology specializing in Holotomography. The company has successfully raised funding through four deals, with the most recent being a Series C round in September 2021, securing KRW 21.2 billion. The founders, Kihyun Hong and YongKeun Park, have directed the company towards innovative imaging solutions for research and pharmaceutical applications.Tomocube specializes in advanced 3D microscopic imaging technology through its flagship product, Holotomography, which allows for non-invasive, label-free observation of biological samples. The core offering, the HT-X1™ Plus, integrates holotomography with artificial intelligence and multimodal imaging capabilities, including epifluorescence and spinning disk confocal optics. This state-of-the-art system is designed to meet the needs of researchers in fields such as regenerative medicine, disease modeling, and drug discovery, enabling high-resolution data acquisition that is crucial for live-cell imaging and analysis. The target clientele includes academic institutions, research laboratories, and pharmaceutical companies engaged in cellular and subcellular research. Geographically, Tomocube's products are marketed in diverse international markets, including North America, Europe, and Asia, catering to a wide range of research applications across these regions.Tomocube generates revenue through the sale of its Holotomography systems and associated software solutions, including the TomoAnalysis suite for comprehensive data analysis. Transactions typically occur through a direct sales model to research institutions and pharmaceutical companies, where clients acquire the HT-X1™ Plus and related products to enhance their scientific capabilities. The company structures its pricing around capital expenditures for the initial equipment purchase, as well as ongoing service agreements for software updates and technical support. Additionally, Tomocube engages in partnerships with research institutions for collaborative projects, further driving revenue through shared initiatives and license agreements. Specific pricing details for individual products or services are not disclosed.In September 2021, Tomocube raised KRW 21.2 billion in Series C funding from investors including DAYLI Partners, IBK Capital, and Korea Investment Private Equity. The company intends to utilize this funding to support the development of new products and enhance its market presence. Plans include the introduction of advanced imaging systems and expansion into North America and Europe by 2023, capitalizing on the growing demand for innovative imaging solutions in scientific research.

## Funding rounds

- Series C, Sep 23, 2021, $18M — SKS, Korea Investment Private Equity, IBK Securities, IBK Capital, Time Folio Asset Management, DAYLI Partners, Ryukyung PSG Asset Management, Leading Ace Capital
- Series B, Aug 28, 2019, $12M — InterVest, Company K Partners, DAYLI Partners
- Series B, Apr 10, 2018, $4.7M — InterVest, SBVA, Company K Partners
- Series A, Mar 29, 2016, $2.5M — SBVA, Hanmi Science Co., Ltd.

## Investors

- SBVA (https://capitalatlas.ai/funds/sbva) — Series A, Series B
- Hanmi Science Co., Ltd. — Series A
- InterVest (https://capitalatlas.ai/funds/intervest) — Series B
- Company K Partners (https://capitalatlas.ai/funds/company-k-partners) — Series B
- DAYLI Partners (https://capitalatlas.ai/funds/dayli-partners) — Series B, Series C
- SKS (https://capitalatlas.ai/funds/sks) — Series C
- Korea Investment Private Equity (https://capitalatlas.ai/funds/korea-investment-private-equity) — Series C
- IBK Securities (https://capitalatlas.ai/funds/ibk-securities) — Series C
- IBK Capital (https://capitalatlas.ai/funds/ibk-capital) — Series C
- Time Folio Asset Management — Series C
- Ryukyung PSG Asset Management — Series C
- Leading Ace Capital — Series C